Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Diabetic nephropathy

SGLT2 inhibitors might halt progression of diabetic nephropathy

Blood pressure lowering slows the progression of diabetic nephropathy whereas the effects of glycaemic control are smaller and slower. New findings from the EMA-REG OUTCOME investigators indicate that SGLT2 inhibition slows the progression of kidney disease by lowering glucose and blood pressure, thereby lowering the risk of adverse renal outcomes in this patient group.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807–814 (2012).

    Article  Google Scholar 

  2. Saran, R. et al. US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 67, A7–A8 (2016).

    Article  Google Scholar 

  3. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1515920 (2016).

  4. Kalaitzidis, R. & Bakris, G. L. in Handbook of Chronic Kidney Disease Management (ed Daugirdas, J.) 224–239 (Lippincott, 2011).

    Google Scholar 

  5. Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).

    Article  Google Scholar 

  6. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  7. Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587–597 (2014).

    Article  CAS  Google Scholar 

  8. Tikkanen, I. et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38, 420–428 (2015).

    Article  CAS  Google Scholar 

  9. Oliva, R. V. & Bakris, G. L. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 8, 330–339 (2014).

    Article  CAS  Google Scholar 

  10. Rafiq, K. et al. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58, 2885–2898 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to George L. Bakris.

Ethics declarations

Competing interests

G.L.B. has consulted for Bayer, Boehringer-Ingelheim, Takeda, AbbVie, Janssen, Merck, Astra-Zeneca and Relypsa. H.Y. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamout, H., Bakris, G. SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol 12, 583–584 (2016). https://doi.org/10.1038/nrneph.2016.109

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2016.109

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing